VAXIMM AG
VAXIMM Announces Presentations at ASCO 2019 and Other Upcoming Industry and Scientific Events
DGAP-News: VAXIMM AG / Key word(s): Conference VAXIMM Announces Presentations at ASCO 2019 and Other Upcoming Industry and Scientific Events Basel (Switzerland) and Mannheim (Germany), April 18, 2019 – VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company will present an abstract about the design of its ongoing trial in patients with glioblastoma with VXM01 oral T-cell immunotherapy in combination with the anti-PD-L1 checkpoint inhibitor avelumab at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. 2019 ASCO (American Society of Clinical Oncology) Annual Meeting The abstract (#269161) “Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071” will be presented during Poster Session: Central Nervous System Tumors, on June 2, 2019, 8:00 AM-11:00 AM CDT. The abstract will be available online on May 15, 2019 at 5 PM EDT at http://abstracts.asco.org. Additionally, the Company will participate in several other industry and scientific events in the second quarter of 2019. European Neoantigen Summit VAXIMM representatives will be available for one-on-one meetings during the summit. To schedule a meeting with VAXIMM, please contact info@vaximm.com. BioEquity Europe Dr. Heinz Lubenau, Chief Operating Officer of VAXIMM, will give a corporate presentation. The Company will also host one-on-one meetings at this event. To request a meeting with VAXIMM, please sign up through the event’s meeting system. 17th CIMT (Association for Cancer Immunotherapy) Annual Meeting VAXIMM representatives will be available for one-on-one meetings during the event. To schedule a meeting with VAXIMM, please contact info@vaximm.com. About VAXIMM Contact:
18.04.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |